Heart Failure: What are the practical consequences of current and ongoing SGLT2i outcome trials?

10' education - Oct. 15, 2019 - Prof. Faiez Zannad, MD - Nancy, France

Video navigation menu

SGLT2i CVOTs in T2DM 0:51
RCTs with SGLT2i in HF 2:37
The DAPA-HF trial: outcomes and key messages 6:03
Traffic jam expected for drug therapy in HFrEF 8:50
Possible mechanisms of action of SGLT2i 10:30

Educational information

This lecture by prof. Faiez Zannad was part of an accredited symposium "Expanding opportunities for SGLT2i in clinical cardiology" held during ESC 2019 in Paris, France.

Faculty

Faiez Zannad is Professor of Therapeutics and Cardiology and Head of the Division of Heart Failure, Hypertension and Preventive Cardiology for the department of Cardiovascular Disease of the Academic Hospital (CHU) in Nancy, France. He is also Director of the Clinical Investigation Centre (Inserm-CHU) in Nancy.

Disclosures

This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.

Funding

Funding for this educational program was provided by an unrestricted educational grant from Boehringer Ingelheim/Lilly.

View slides of this presentation Click here for the meeting report

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.